Pay in 4 interest-free payments of $5.15 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Repeat imaging at 612 months helps assess treatment response, with clinically meaningful improvement defined as at least a 30% relative reduction in hepatic fat content
To view or add a comment, sign in Everyone's debating which FMCG categories GLP-1 drugs will hurt most
GLP-1s may lower the risk and severity of metabolic syndrome Those with metabolic syndrome have a higher chance of experiencing health issues like type 2 diabetes, stroke, and coronary heart diseaseserious conditions that can shorten your life
For example, in Canada, attention is already shifting towards newer entrants like tirzepatide (Mounjaro/Zepbound), which has demonstrated superior efficacy in weight loss in the head-to-head SURMOUNT-5 trial iii and is gaining momentum
)
)
)
